A Phase 2 interventional study of AZD3427 and Placebo in Pulmonary Hypertension (World Health Organization Group 2) and Heart Failure, sponsored by AstraZeneca. Completed at 60 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 38th largest by enrollment of the 286 interventional ones that give a count, is one of 15 that started in 2023, is one of 93 in phase 2, and was the 328th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of California, Davis · Sites in United States
Ages up to 28 days
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States
Ages 18+
National Institutes of Health Clinical Center (CC) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
397 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 114 · Phase 3 75 · Phase 4 38
First in 1992; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 286 interventional studies, 108 across the 107 observational. Of the 274 that completed or were terminated, 139 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
158 of 397 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
AstraZeneca has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
21 of the studies in Hypertension, Pulmonary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
| NCT05442671Children's Hospital of PhiladelphiaiTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH | 2026-12-31 |
| NCT04808596University of Kansas Medical CenterPulmonary Hypertension Biorepository and Registry | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 397 studies in Hypertension, Pulmonary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
This study is a randomized, placebo-controlled, multi-centre, dose-ranging study of AZD3427 in participants with heart failure and pulmonary hypertension due to left heart disease (World Health Organisation [WHO] Group 2).
Approximately 220 participants will be randomised to 4 treatment groups (in a 1:1:1:1 ratio) to receive a subcutaneous (SC) injection of AZD3427 or placebo every 2 weeks for 24 weeks.
This study will evaluate 3 dose levels of AZD3427: Dose A, Dose B, and Dose C. Dose modification is not applicable for this study.
The study will be conducted in approximately 60 study centres across an estimated 15 countries.
The study will include approximately 16 study visits: 2 visits during the Screening Period,13 visits during the Treatment Period, and one visit during the Follow-up Period.
The expected total duration of the study is 32 to 37 weeks, depending on the length of the Screening Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have an on-study elevated pulmonary artery pressure from RHC performed as per RHC manual provided by the Sponsor, at Screening Visit 2:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants will receive single dose of AZD3427 Dose A every 2 weeks for 24 weeks from Day 1 to Day 155.
Drug: AZD3427
The participants will receive single dose of AZD3427 Dose B every 2 weeks for 24 weeks from Day 1 to Day 155.
Drug: AZD3427
The participants will receive single dose of AZD3427 Dose C every 2 weeks for 24 weeks from Day 1 to Day 155.
Drug: AZD3427
The participants will receive single dose of placebo every 2 weeks for 24 weeks from Day 1 to Day 155.
Drug: Placebo
The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
Change From Baseline in Pulmonary Vascular Resistance (PVR)
The effect of AZD3427 compared with placebo on PVR parameter as measured by right heart catheterization (RHC-a procedure which allows measurement of blood pressure in the right side of the heart) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2 was evaluated. PVR was calculated using formula, PVR=80\* \[Mean pulmonary arterial pressure\[mPAP\](mmHg)- Pulmonary artery wedge pressure\[PAWP\](mmHg)\]/Cardiac output (L/min). Baseline was defined as last non-missing value prior to or on the date of first study intervention dose. PVR was originally measured in dynes·sec/cm⁵. For the statistical analysis, PVR values were log-transformed, and change from baseline was assessed on the log-transformed scale. Results were subsequently back-transformed and presented on the original scale as the ratio of post-baseline to baseline PVR. Therefore, the unit of measure for this endpoint is a ratio. The measure type is geometric mean ratio.
Time frame: Baseline to Week 25
Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP)
The effect of AZD3427 compared with placebo on mPAP parameter as measured by RHC after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Pulmonary Artery Wedge Pressure (PAWP)
The effect of AZD3427 compared with placebo on PAWP parameter as measured by RHC after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. PAWP was measured in mmHg. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio. The measure type is geometric mean ratio.
Time frame: Baseline to Week 25
Change From Baseline in Cardiac Output (CO) ECHO
The effect of AZD3427 compared with placebo on CO parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Left Ventricular Stroke Volume (LV SV)
The effect of AZD3427 compared with placebo on LV SV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
The effect of AZD3427 compared with placebo on EF parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Left Ventricular Global Longitudinal Strain (LVGLS)
The effect of AZD3427 compared with placebo on LVGLS parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. LVGLS is measured by echocardiograohy. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)
The effect of AZD3427 compared with placebo on PASP parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Right Ventricle/Left Ventricle (RV/LV) Ratio
The effect of AZD3427 compared with placebo on RV/LV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Right Ventricular Outflow Tract Acceleration Time (RVOT AT)
The effect of AZD3427 compared with placebo on RVOT AT parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Tricuspid Regurgitation Velocity (TRV)
The effect of AZD3427 compared with placebo on TRV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. TRV was measured by Echocardiography. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in TAPSE/PASP [Tricuspid Annular Plane Systolic Excursion/ Pulmonary Arterial Systolic Pressure]
The effect of AZD3427 compared with placebo on TAPSE/PASP parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Systemic Vascular Resistance (SVR)
The effect of AZD3427 compared with placebo on systemic vascular resistance parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. SVR was measured by Echocardipgraphy. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in 6-minute Walking Distance (6MWD)
The effect of AZD3427 compared with placebo on function and symptoms using 6MWD parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS)
The effect of AZD3427 compared with placebo on function and symptoms using KCCQ TSS parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. The score ranged from 0 to 100, where a higher score represents a better patient outcome. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Number of Participants With Improved Change From Baseline in New York Heart Association Functional Class (NYHA FC)
The effect of AZD3427 compared with placebo on function and symptoms using NYHA FC parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 25
Change From Baseline in Serum Creatinine
The effect of AZD3427 compared with placebo using serum creatinine parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. Creatinine was measured in micromoles/liter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.
Time frame: Baseline to Week 13 and Week 25
Change From Baseline in N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)
The effect of AZD3427 compared with placebo using NT-proBNP parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. NT-ProBNP was measured in picomole/Liter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.
Time frame: Baseline to Week 13 and Week 25
Change From Baseline in Cystatin C
The effect of AZD3427 compared with placebo using cystatin C parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. Cystatin C was measured in milligram/deciliter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.
Time frame: Baseline to Week 13 and Week 25
Change From Baseline in eGFR (Estimated Glomerular Filtration Rate)
The effect of AZD3427 compared with placebo using eGFR parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
Time frame: Baseline to Week 13 and Week 25
AZD3427 Serum Concentration
Serum concentration of AZD3427 was summarised by timepoints and dose level. This was done to evaluate the pharmacokinetics (PK) of AZD3427 after dosing in participants with HF and PH Group 2. Considering the approximately 13-14 days half-life of AZD3427, low or non-quantifiable serum concentrations at Week 31 are not unexpected. Therefore, the presentation of the Week 31 results, including the reported NA values, reflects the prespecified statistical handling of the data and the observed concentration profile.
Time frame: On Week 3, Week 5, Week 13, Week 19, Week 25 and Week 31
Number of Participants With Presence of Anti-drug Antibodies (ADAs)
The immunogenicity of AZD3427 was evaluated as measured by ADAs. The number of participants with treatment emergent (TE) ADA positive samples have been reported as they account for the ADA incidence during the study.
Time frame: From Day 1 up to Day 211
Evaluation of Positive ADA Titer
The immunogenicity of AZD3427 as measured by ADAs was evaluated. ADA titer was summarized descriptively as a continuous variable, with median, minimum and maximum values. The antibody titer for the TE-ADA positive (ADA incidence) participants have been reported. It is defined as the sum of treatment-induced ADA (post-baseline positive only) and treatment-boosted ADA. Combined timepoint is used in summary for subject-level overall ADA status (i.e. TE-ADA positive). The summary statistics were calculated based on the maximum post-baseline titre for each ADA-positive subject within each treatment group,'
Time frame: At Day 1, Day 15, Day 29, Day 85, Day 169 and Day 211.
Number of Participants With Adverse Events and Serious Adverse Events
The safety and tolerability of AZD3427 as compared to placebo in participants with HF and PH Group 2 were evaluated. Only treatment emergent adverse events (TEAEs) which had an onset after randomization have been reported here.
Time frame: From Randomization (Day 1) up to Follow-up Visit (Day 211)
The study was conducted from 24-April-2023 (study start date) to 25-August-2025 (last participant last visit) in 66 study centres across 14 countries; 62 study centres screened participants and of these 52 study centres randomized participants.
| Milestone | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Started | 65 | 66 | 63 | 65 |
| Completed | 61 | 59 | 58 | 58 |
| Not completed | 4 | 7 | 5 | 7 |
| Withdrew: Subject decision | 2 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 2 | 6 | 2 | 4 |
The effect of AZD3427 compared with placebo on PVR parameter as measured by right heart catheterization (RHC-a procedure which allows measurement of blood pressure in the right side of the heart) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2 was evaluated. PVR was calculated using formula, PVR=80\* \[Mean pulmonary arterial pressure\[mPAP\](mmHg)- Pulmonary artery wedge pressure\[PAWP\](mmHg)\]/Cardiac output (L/min). Baseline was defined as last non-missing value prior to or on the date of first study intervention dose. PVR was originally measured in dynes·sec/cm⁵. For the statistical analysis, PVR values were log-transformed, and change from baseline was assessed on the log-transformed scale. Results were subsequently back-transformed and presented on the original scale as the ratio of post-baseline to baseline PVR. Therefore, the unit of measure for this endpoint is a ratio. The measure type is geometric mean ratio.
| Ratio | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Pulmonary Vascular Resistance (PVR) | 1.002 (0.862 to 1.164) | 1.221 (1.054 to 1.415) | 0.950 (0.815 to 1.109) | 1.056 (0.908 to 1.228) |
The effect of AZD3427 compared with placebo on mPAP parameter as measured by RHC after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| millimeters of mercury (mmHg) | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) | -3.417 (-5.304 to -1.531) | -2.005 (-3.892 to -0.119) | -2.642 (-4.605 to -0.678) | -2.306 (-4.236 to -0.376) |
The effect of AZD3427 compared with placebo on PAWP parameter as measured by RHC after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. PAWP was measured in mmHg. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio. The measure type is geometric mean ratio.
| Ratio | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Pulmonary Artery Wedge Pressure (PAWP) | 0.800 (0.726 to 0.882) | 0.821 (0.746 to 0.903) | 0.842 (0.763 to 0.929) | 0.837 (0.759 to 0.924) |
The effect of AZD3427 compared with placebo on CO parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| Liter/minute (L/min) | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Cardiac Output (CO) ECHO | -0.114 (-0.494 to 0.266) | -0.456 (-0.828 to -0.084) | -0.429 (-0.805 to -0.052) | -0.357 (-0.729 to 0.015) |
The effect of AZD3427 compared with placebo on LV SV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| milliliters (mL) | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Left Ventricular Stroke Volume (LV SV) | -5.512 (-9.905 to -1.119) | -8.986 (-13.345 to -4.628) | -7.605 (-11.975 to -3.235) | -6.903 (-11.140 to -2.667) |
The effect of AZD3427 compared with placebo on EF parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| Percentage | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Left Ventricular Ejection Fraction (LVEF) | 0.122 (-1.459 to 1.703) | -0.046 (-1.652 to 1.559) | 0.074 (-1.596 to 1.744) | -0.389 (-1.968 to 1.190) |
The effect of AZD3427 compared with placebo on LVGLS parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. LVGLS is measured by echocardiograohy. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| Percentage | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Left Ventricular Global Longitudinal Strain (LVGLS) | 0.658 (-0.301 to 1.618) | 0.476 (-0.522 to 1.475) | 0.252 (-0.706 to 1.210) | 0.904 (-0.047 to 1.854) |
The effect of AZD3427 compared with placebo on PASP parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| mmHg | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP) | -0.608 (-4.267 to 3.051) | -3.609 (-7.576 to 0.357) | -1.943 (-5.766 to 1.880) | -0.962 (-4.993 to 3.070) |
The effect of AZD3427 compared with placebo on RV/LV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| Ratio | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Right Ventricle/Left Ventricle (RV/LV) Ratio | -0.003 (-0.032 to 0.026) | -0.030 (-0.059 to 0.000) | -0.026 (-0.055 to 0.004) | -0.018 (-0.047 to 0.012) |
The effect of AZD3427 compared with placebo on RVOT AT parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| milliseconds (ms) | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Right Ventricular Outflow Tract Acceleration Time (RVOT AT) | -7.042 (-18.193 to 4.108) | -0.409 (-11.934 to 11.115) | 3.346 (-8.294 to 14.987) | -3.481 (-14.131 to 7.169) |
The effect of AZD3427 compared with placebo on TRV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. TRV was measured by Echocardiography. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| centimeter/second (cm/s) | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Tricuspid Regurgitation Velocity (TRV) | -0.850 (-13.947 to 12.247) | -10.512 (-24.468 to 3.445) | -6.110 (-20.022 to 7.802) | 0.859 (-13.700 to 15.418) |
The effect of AZD3427 compared with placebo on TAPSE/PASP parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| cm/mmHg | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in TAPSE/PASP [Tricuspid Annular Plane Systolic Excursion/ Pulmonary Arterial Systolic Pressure] | 0.002 (-0.005 to 0.009) | 0.004 (-0.002 to 0.011) | 0.000 (-0.006 to 0.007) | 0.005 (-0.002 to 0.012) |
The effect of AZD3427 compared with placebo on systemic vascular resistance parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. SVR was measured by Echocardipgraphy. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| dynes*s*cm^-5 | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Systemic Vascular Resistance (SVR) | -1.968 (-166.324 to 162.388) | 34.970 (-138.860 to 208.801) | 60.014 (-109.154 to 229.183) | 97.933 (-68.521 to 264.388) |
The effect of AZD3427 compared with placebo on function and symptoms using 6MWD parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| meter (m) | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in 6-minute Walking Distance (6MWD) | 2.299 (-19.504 to 24.102) | 6.092 (-15.819 to 28.003) | 7.791 (-14.383 to 29.966) | 15.195 (-6.949 to 37.340) |
The effect of AZD3427 compared with placebo on function and symptoms using KCCQ TSS parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. The score ranged from 0 to 100, where a higher score represents a better patient outcome. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| Score on scale | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) | 6.45 ± 19.02 | 10.20 ± 18.20 | 9.98 ± 18.76 | 5.12 ± 18.81 |
The effect of AZD3427 compared with placebo on function and symptoms using NYHA FC parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| Participants | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Improved Change From Baseline in New York Heart Association Functional Class (NYHA FC) | 16 | 16 | 14 | 20 |
The effect of AZD3427 compared with placebo using serum creatinine parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. Creatinine was measured in micromoles/liter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.
| Ratio | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Week 13 | 1.003 (0.956 to 1.052) | 1.002 (0.955 to 1.051) | 0.962 (0.915 to 1.010) | 1.055 (1.005 to 1.108) |
| Week 25 | 0.984 (0.936 to 1.035) | 1.015 (0.963 to 1.069) | 0.968 (0.919 to 1.021) | 1.071 (1.012 to 1.133) |
The effect of AZD3427 compared with placebo using NT-proBNP parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. NT-ProBNP was measured in picomole/Liter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.
| Ratio | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Week 13 | 1.046 (0.914 to 1.196) | 1.051 (0.917 to 1.203) | 1.013 (0.884 to 1.162) | 0.955 (0.832 to 1.095) |
| Week 25 | 0.966 (0.806 to 1.159) | 1.109 (0.920 to 1.336) | 0.988 (0.820 to 1.189) | 1.047 (0.863 to 1.270) |
The effect of AZD3427 compared with placebo using cystatin C parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. Cystatin C was measured in milligram/deciliter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.
| Ratio | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Week 13 | 0.983 (0.938 to 1.030) | 1.015 (0.970 to 1.062) | 0.988 (0.941 to 1.036) | 1.002 (0.956 to 1.050) |
| Week 25 | 0.972 (0.921 to 1.026) | 1.013 (0.961 to 1.069) | 0.990 (0.936 to 1.047) | 1.039 (0.982 to 1.100) |
The effect of AZD3427 compared with placebo using eGFR parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.
| mL/minute/1.73 m^2 (mL/min/1.73 m^2) | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Week 13 | 0.840 (-1.992 to 3.672) | -0.638 (-3.474 to 2.198) | 2.112 (-0.799 to 5.024) | -2.323 (-5.244 to 0.599) |
| Week 25 | 1.355 (-1.755 to 4.466) | -1.380 (-4.488 to 1.727) | 1.636 (-1.562 to 4.8344) | -3.771 (-7.191 to -0.352) |
Serum concentration of AZD3427 was summarised by timepoints and dose level. This was done to evaluate the pharmacokinetics (PK) of AZD3427 after dosing in participants with HF and PH Group 2. Considering the approximately 13-14 days half-life of AZD3427, low or non-quantifiable serum concentrations at Week 31 are not unexpected. Therefore, the presentation of the Week 31 results, including the reported NA values, reflects the prespecified statistical handling of the data and the observed concentration profile.
| microgram/Liter (ug/L ) | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg |
|---|---|---|---|
| Week 3 | 50.27 ± 70.38 | 143.2 ± 53.93 | 501.9 ± 45.04 |
| Week 5 | 60.94 ± 72.99 | 191.5 ± 68.93 | 658.3 ± 56.19 |
| Week 13 | 76.38 ± 80.85 | 214.1 ± 84.42 | 754.3 ± 83.59 |
| Week 19 | 80.5 ± 68.96 | 191.0 ± 83.70 | 786.4 ± 89.92 |
| Week 25 | 86.41 ± 71.99 | 250.8 ± 81.65 | 849.0 ± 78.64 |
| Week 31 | NA ± NA | 23.12 ± 83.64 | 60.18 ± 126.2 |
The immunogenicity of AZD3427 was evaluated as measured by ADAs. The number of participants with treatment emergent (TE) ADA positive samples have been reported as they account for the ADA incidence during the study.
| Count of participants | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Presence of Anti-drug Antibodies (ADAs) | 3 | 9 | 16 | 1 |
The immunogenicity of AZD3427 as measured by ADAs was evaluated. ADA titer was summarized descriptively as a continuous variable, with median, minimum and maximum values. The antibody titer for the TE-ADA positive (ADA incidence) participants have been reported. It is defined as the sum of treatment-induced ADA (post-baseline positive only) and treatment-boosted ADA. Combined timepoint is used in summary for subject-level overall ADA status (i.e. TE-ADA positive). The summary statistics were calculated based on the maximum post-baseline titre for each ADA-positive subject within each treatment group,'
| Titer | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Evaluation of Positive ADA Titer | 50 (50 to 100) | 50 (50 to 400) | 150 (50 to 3200) | NA (400 to 400) |
The safety and tolerability of AZD3427 as compared to placebo in participants with HF and PH Group 2 were evaluated. Only treatment emergent adverse events (TEAEs) which had an onset after randomization have been reported here.
| Count of participants | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Any adverse event (AE) | 47 | 47 | 50 | 46 |
| Any serious adverse event (SAE) | 10 | 13 | 10 | 17 |
| Any SAE with outcome death | 1 | 2 | 0 | 3 |
| Any AE leading to discontinuation of Investigational Product (IP) | 2 | 6 | 3 | 4 |
| Any AE leading to withdrawal from study | 1 | 4 | 3 | 3 |
Collected over Until follow up visit (Day 211). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD3427 Dose 1.1 mg | 1/65 (1.5%) | 11/65 (16.9%) | 28/65 (43.1%) |
| AZD3427 Dose 5.4 mg | 2/66 (3%) | 14/66 (21.2%) | 22/66 (33.3%) |
| AZD3427 Dose 30.0 mg | 0/63 (0%) | 10/63 (15.9%) | 29/63 (46%) |
| Placebo | 3/65 (4.6%) | 17/65 (26.2%) | 23/65 (35.4%) |
| Event | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| Cardiac failureCardiac disorders | 4/65 | 6/66 | 1/63 | 7/65 |
| PneumoniaInfections and infestations | 1/65 | 0/66 | 1/63 | 3/65 |
| Cardiac failure congestiveCardiac disorders | 0/65 | 0/66 | 2/63 | 0/65 |
| Cardiac arrestCardiac disorders | 0/65 | 0/66 | 0/63 | 2/65 |
| Ventricular tachycardiaCardiac disorders | 0/65 | 0/66 | 0/63 | 2/65 |
| AnaemiaBlood and lymphatic system disorders | 1/65 | 2/66 | 1/63 | 0/65 |
| Cardiac failure acuteCardiac disorders | 0/65 | 2/66 | 1/63 | 1/65 |
| CellulitisInfections and infestations | 0/65 | 0/66 | 1/63 | 0/65 |
| DiverticulitisInfections and infestations | 0/65 | 0/66 | 1/63 | 0/65 |
| Pneumonia bacterialInfections and infestations | 0/65 | 0/66 | 1/63 | 0/65 |
| Event | AZD3427 Dose 1.1 mg | AZD3427 Dose 5.4 mg | AZD3427 Dose 30.0 mg | Placebo |
|---|---|---|---|---|
| HypotensionVascular disorders | 6/65 | 4/66 | 7/63 | 2/65 |
| Oedema peripheralGeneral disorders | 3/65 | 4/66 | 6/63 | 5/65 |
| Upper respiratory tract infectionInfections and infestations | 6/65 | 2/66 | 5/63 | 1/65 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/65 | 6/66 | 4/63 | 2/65 |
| Urinary tract infectionInfections and infestations | 4/65 | 3/66 | 5/63 | 3/65 |
| Cardiac failureCardiac disorders | 5/65 | 1/66 | 5/63 | 4/65 |
| NasopharyngitisInfections and infestations | 1/65 | 3/66 | 3/63 | 5/65 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/65 | 2/66 | 0/63 | 1/65 |
| HypokalaemiaMetabolism and nutrition disorders | 2/65 | 4/66 | 4/63 | 1/65 |
| FallInjury, poisoning and procedural complications | 2/65 | 2/66 | 4/63 | 0/65 |
The Full Analysis Set consisted of all participants who were randomized and had received at least one dose of study intervention.
| Age, Continuous(Years) | AZD3427 1.1 mg | AZD3427 5.4 mg | AZD3427 30.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 71.2 ± 13.3 | 70.2 ± 13.2 | 69.2 ± 14.0 | 66.5 ± 12.4 | 69.3 ± 13.3 |
| Sex: Female, Male(Participants) | AZD3427 1.1 mg | AZD3427 5.4 mg | AZD3427 30.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 31 | 38 | 34 | 28 | 131 |
| Male | 34 | 28 | 29 | 37 | 128 |
| Race/Ethnicity, Customized(Participants) | AZD3427 1.1 mg | AZD3427 5.4 mg | AZD3427 30.0 mg | Placebo | Total |
|---|---|---|---|---|---|
| White | 54 | 51 | 52 | 55 | 212 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 7 | 9 | 8 | 7 | 31 |
| Black or African American | 2 | 5 | 2 | 0 | 9 |
| Hawaiian Native or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 1 | 1 |
| Not Reported | 2 | 1 | 1 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Apr 2023 to primary completion in Jul 2025, 26 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD3427